Non-replicating Protein Nanoparticle-based Rotavirus Vaccine

InThera, with support from the RIGHT Foundation, is developing a next-generation parenteral rotavirus vaccine (ENC-P[8]/P[6]/P[4] VP8)* to address the limitations of current oral rotavirus vaccines (ORVs). While ORVs have reduced severe diarrhea globally, their effectiveness is lower in middle- and high-burden regions, and concerns persist about rare adverse events like intussusception. The ENC VP8 nanoparticle vaccine*, expressed in E. coli and adsorbed to aluminum hydroxide gel, targets the major circulating human rotavirus genotypes (P[4], P[6], and P[8]) and elicits a superior immune response via intramuscular administration. This novel approach aims to provide higher efficacy and broader protection, particularly in middle-income countries not eligible for Gavi funding. By overcoming the challenges of ORVs, InThera’s vaccine could significantly reduce rotavirus-related deaths and improve public health outcomes worldwide.